Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Grit AndersenGursharan SinghSundara Moorthi Nainar MurugesanRajesh GogineniNirant SharmaJayanti PandaAshwani MarwahSubramanian LoganathanSandeep N AthalyePublished in: Diabetes, obesity & metabolism (2023)
PK and PD equivalence was demonstrated between Biocon's Insulin-N and Humulin-N in healthy subjects and both treatments were well tolerated and considered safe. This article is protected by copyright. All rights reserved.